One of the most challenging fields for pharmaceutical and biotechnological products is the
drug delivery to the central nervous system. According to the WHO records, 6.8 million …

Background The blood-brain barrier (BBB) is a complex and dynamic structure that serves
as a gatekeeper, restricting the migrations of most compounds and molecules from blood …

The blood-brain barrier (BBB) protects the central nervous system, one of the body's most
fragile microenvironments, by controlling its homeostasis. The BBB is a very complex system …

The blood–brain barrier (BBB) is a highly regulated and efficient barrier that provides a
sanctuary to the brain. It is designed to regulate brain homeostasis and to permit selective …

Drug delivery to brain is still a challenging task due to the presence of the blood–brain
barrier (BBB), a very restrictive barrier mainly composed of tightly sealed endothelial cells …

The administration of drugs to the CNS has become a difficult task because several barriers
in the brain, ie the blood-brain barrier (BBB) and a blood-cerebrospinal fluid barrier must be …

Neuropharmaceutics is the largest potential growth sector of the pharmaceutical industry.
However, this growth is blocked by the problem of the blood–brain barrier (BBB). Essentially …

The blood–brain barrier (BBB) denies many therapeutic agents access to brain tumours and
other diseases of the central nervous system (CNS). Despite remarkable advances in our …

The objective of this article is to provide the reader with an update on some research
highlights from the past to the present, as well as future possibilities to achieve improved …

The development of new drugs is expensive and time-consuming. Most of the potential
compounds lack therapeutic efficacy due to their inability to reach the target site. An …